Bulletin du cancer最新文献

Patient views on continued immune checkpoint inhibition following progression in advanced melanoma: A qualitative study. 晚期黑色素瘤进展后患者对继续使用免疫检查点抑制剂的看法：一项定性研究。

Bulletin du cancer Pub Date : 2025-01-11 DOI: 10.1016/j.bulcan.2024.12.011

Chloé Prod'homme, Nicolas Sena, Emmanuelle Forestier, Rozenn Le Berre, Eve Desmedt, Laurent Mortier, Licia Touzet

{"title":"Patient views on continued immune checkpoint inhibition following progression in advanced melanoma: A qualitative study.","authors":"Chloé Prod'homme, Nicolas Sena, Emmanuelle Forestier, Rozenn Le Berre, Eve Desmedt, Laurent Mortier, Licia Touzet","doi":"10.1016/j.bulcan.2024.12.011","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.12.011","url":null,"abstract":"Introduction: Immune checkpoint inhibition has revolutionized the management of metastatic melanoma, including in the final stages of disease progression: because it is well tolerated, some teams do not discontinue it in hopes of slowing disease progression. The risks are that treatment may be continued unnecessarily, causing side effects, and reduce access to specialist palliative care, in addition to increasing the cost of treatment.Method: We explored the experiences of 10 patients in a university hospital with metastatic melanoma under continued immune checkpoint inhibitors combined with specialist palliative care. Our goal was to gain a better understanding of the advantages and disadvantages perceived by patients. The comprehensive interviews were analysed using a method inspired by grounded theory that met the COREQ international recommendation criteria.Results: Receiving the information of disease progression, continued treatment and onset of palliative care impacts patients' lives: from this point onwards, death becomes a reality and takes on the image of a sword of Damocles. The experience is anxiety-provoking because of the uncertainty of tomorrow, and painful because of the physical suffering and successive bereavements. However, far from causing depression and despair, joint oncology-palliative management is well accepted and helps to improve patients' daily lives and well-being.Conclusion: Our findings highlight patients' ambivalence. On the one hand, they recount their experiences of suffering in connection with the disease and the confrontation with death, and on the other hand, their need to continue to live and to hope. Joint care provided by oncology and palliative care teams, symbolically representing hope and death, may mirror patients' psychological mindset and provide just the support they need.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of immune characteristics of two lung adenocarcinoma subtypes based on immune- and pyroptosis-related genes to improve immunotherapy. 基于免疫和焦热相关基因鉴定两种肺腺癌亚型的免疫特性以改进免疫治疗

Bulletin du cancer Pub Date : 2025-01-03 DOI: 10.1016/j.bulcan.2024.11.009

Yifan Tie, Jinzhi Xu

{"title":"Identification of immune characteristics of two lung adenocarcinoma subtypes based on immune- and pyroptosis-related genes to improve immunotherapy.","authors":"Yifan Tie, Jinzhi Xu","doi":"10.1016/j.bulcan.2024.11.009","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.11.009","url":null,"abstract":"Background: Lung adenocarcinoma (LUAD) is the most prevalent histological subtype of lung cancer. Pyroptosis is a programmatic cell death linked to inflammation.Methods: The data information of 541 LUAD samples and 59 normal samples were obtained from TCGA database. The analysis of differentially expressed genes (DEGs) was carried out on LUAD patients. The intersection of integrated PRGs and IRGs with DEGs yielded IPRGs. We utilized univariate Cox regression to determine IPRGs linked to overall survival (OS). Based on their expression levels, unsupervised clustering of LUAD was conducted. Patients were divided into two clusters. Analyses of immunity and drugs were performed in two clusters.Results: One hundred and thirty-two IPRGs were linked with OS. Cluster 1 had a longer OS. Two thousand two hundred and fifty-six DEGs were detected in various subtypes. The results of immune analysis showed that most of the immune cells in cluster 2, which had a worse prognosis, had a low degree of infiltration. High Th2 cell infiltration may be related to poor prognosis in LUAD patients. Higher tumor immune dysfunction and exclusion (TIDE) and immunophenotypic scores in Cluster 1 indicated that these patients may have a better response to immunotherapy. There were significant differences in human leukocyte antigen (HLA), immune checkpoints, immunophenoscore (IPS), and TIDE scores in the two subtypes. The mutation frequencies of the top 10 genes in cluster 2 were higher than those in cluster 1. Different subtypes also had distinct sensitivities to different drugs.Conclusion: IPRGs can be utilized for LUAD subtyping. Different subtypes have varied immune landscapes and immunotherapy responses.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Diet guidelines in adult and pediatric patient after allogeneic stem cell transplantation (SFGM-TC)]. [同种异体干细胞移植后成人和儿童患者的饮食指南（SFGM-TC）]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-06-25 DOI: 10.1016/j.bulcan.2024.04.014

Carole Farrugia, Alexandra Lhostette, Marion Brasseur, Thomas Biot, Hélène Calmes, Caroline Dendoncker, Anne Sophie Dupret, Sophie Estheve, Sylivie Filiol, Virginie Guidi, Lisa Hadrot, Manon Perez, Aurélie Ravinet, Laure Tardieu, Léonardo Magro, Serge Alfandari, Nicolas Simon, Sarah Guenounou, Jérôme Cornillon

引用次数: 0

[Update for cord blood unit selection in hematopoietic stem cell transplantation (workshop SFGM-TC)]. [造血干细胞移植中脐带血单位选择的更新（SFGM-TC 研讨会）]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-03-13 DOI: 10.1016/j.bulcan.2024.01.009

Valérie Dubois, Lucie Blandin, Marion Duclaut, Alix Duquesne, Lionel Faivre, Romain Ferru-Clement, Jean Roy, Alexandre Walencik, Leonardo Magro, Federico Garnier

{"title":"[Update for cord blood unit selection in hematopoietic stem cell transplantation (workshop SFGM-TC)].","authors":"Valérie Dubois, Lucie Blandin, Marion Duclaut, Alix Duquesne, Lionel Faivre, Romain Ferru-Clement, Jean Roy, Alexandre Walencik, Leonardo Magro, Federico Garnier","doi":"10.1016/j.bulcan.2024.01.009","DOIUrl":"10.1016/j.bulcan.2024.01.009","url":null,"abstract":"Changing practices and the limited use of cord blood units as a source of cells for allogeneic hematopoietic stem cell transplants (HSC) led us to reconsider the recommendations established in 2011 and 2012, and to propose an update incorporating recent bibliographic data. If HLA compatibility was until now established at low resolution for HLA-A and B loci, and at high resolution for HLA-DRB1, the recent papers are converging towards an increase in the level of resolution, making way for a compatibility now defined in high resolution for all the considered loci, and the inclusion of the HLA-C locus, in order to establish a level of HLA compatibility on 8 alleles (HLA-A, B, C and DRB1). The CD34+ dose is a determining factor in hematopoietic reconstitution but it is not correlated with the total nucleated cells content. This is why we recommend taking these two data into account when choosing a cord blood unit. The recommendations established by our group are presented as a flow chart taking into account the characteristics of the underlying pathology (malignant or non-malignant), the cell dose and the HLA compatibility criteria, as well as criteria linked to the banks in which units are stored.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S68-S77"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Survival after cancer on Reunion Island]. [留尼汪岛癌症后的生存]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-12-16 DOI: 10.1016/j.bulcan.2024.12.003

Mohamed Khettab, Franck Ah-Pine, Emeline Colomba, Phuong Lien Tran, Jean-François Delattre, Luc Bauchet, Emmanuel Chirpaz

引用次数: 0

[Pre-, per- and post-allogeneic haematopoietic stem cell transplant rehabilitation (SFGM-TC)]. [异体造血干细胞移植前、移植前和移植后的康复（Atelier SFGM-TC）]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-07-08 DOI: 10.1016/j.bulcan.2024.05.006

Virgile Pinelli, Laure Christophe, Nathalie Cheron, Sarah Morin, Lila Gilis, Candy Heuze, Dominique Clerc-Renaud, Laurence Morotti, Benoit Vilhet, Sandra Bissardon, Leonardo Magro

{"title":"[Pre-, per- and post-allogeneic haematopoietic stem cell transplant rehabilitation (SFGM-TC)].","authors":"Virgile Pinelli, Laure Christophe, Nathalie Cheron, Sarah Morin, Lila Gilis, Candy Heuze, Dominique Clerc-Renaud, Laurence Morotti, Benoit Vilhet, Sandra Bissardon, Leonardo Magro","doi":"10.1016/j.bulcan.2024.05.006","DOIUrl":"10.1016/j.bulcan.2024.05.006","url":null,"abstract":"Allogeneic transplantation of haematopoietic stem cells is still the only curative treatment for certain haematological malignancies. This treatment can be responsible for a number of side-effects, leading to multiple and interdependent physical and psychological deficiencies that affect patients' quality of life and social participation, and can be experienced as a handicap, sometimes for several years after the transplant. For several years now, the integration of post-transplant rehabilitation pathways has been becoming more widespread, and initiatives to provide multidisciplinary care at an increasingly early stage are being studied. The aim of this early management is to improve the patient's overall functional state before, during and after the transplant, in order to limit the impact of the treatment and ensure the quickest possible return to a life that is as satisfying as possible. The international literature and the experiments carried out throughout the French-speaking world describe heterogeneous practices. Based on this literature and experience, the aim of this study is to issue homogenous recommendations for good clinical practice and to identify areas for further research into pre-transplant, per-transplant and post-transplant rehabilitation of haematopoietic stem cells.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S2-S9"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141565575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Preventive and therapeutic strategies for relapse after hematopoietic stem cell transplant for pediatric AML (SFGM-TC)]. [小儿急性髓细胞性白血病造血干细胞移植后复发的预防和治疗策略（SFGM-TC）]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-06-25 DOI: 10.1016/j.bulcan.2024.02.006

Cécile Renard, Alizee Corbel, Catherine Paillard, Cécile Pochon, Pascale Schneider, Nicolas Simon, Nimrod Buchbinder, Mony Fahd, Ibrahim Yakoub-Agha, Charlotte Calvo

{"title":"[Preventive and therapeutic strategies for relapse after hematopoietic stem cell transplant for pediatric AML (SFGM-TC)].","authors":"Cécile Renard, Alizee Corbel, Catherine Paillard, Cécile Pochon, Pascale Schneider, Nicolas Simon, Nimrod Buchbinder, Mony Fahd, Ibrahim Yakoub-Agha, Charlotte Calvo","doi":"10.1016/j.bulcan.2024.02.006","DOIUrl":"10.1016/j.bulcan.2024.02.006","url":null,"abstract":"Treatment of pediatric high-risk acute myeloid leukemia (AML), defined either on molecular or cytogenetic features, relies on bone marrow transplant after cytologic remission. However, relapse remains the first post-transplant cause of mortality. In this 13th session of practice harmonization of the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC), our group worked on recommendations regarding the management of post-transplant relapse in AML pediatric patients based on international literature, national survey and expert opinion. Overall, immunomodulation strategy relying on both measurable residual disease (MRD) and chimerism evaluation should be used for high-risk AML. In very high-risk (VHR) AML with a 5-year overall survival ≤30 %, a post-transplant maintenance should be proposed using either hypomethylating agents, combined with DLI whenever possible, or FLT3 tyrosine kinase inhibitors if this target is present on leukemia cells. In the pre-emptive or early relapse settings (< 6 months post-transplant), treatments combining DLI, Azacytidine and Venetoclax should be considered. Access to phase I/II trails for targeted therapies (menin, IDH or JAK inhibitors) should be discussed in each patient according to the underlying molecular abnormalities of the disease.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S135-S145"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Triple negative breast cancer: Current status and perspectives]. [三阴性乳腺癌：现状与展望]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-11-06 DOI: 10.1016/j.bulcan.2024.09.002

Fanny Le Du, Emilie Moati, Pauline Vaflard, Caroline Bailleux, Jean-Yves Pierga, Véronique Dieras

{"title":"[Triple negative breast cancer: Current status and perspectives].","authors":"Fanny Le Du, Emilie Moati, Pauline Vaflard, Caroline Bailleux, Jean-Yves Pierga, Véronique Dieras","doi":"10.1016/j.bulcan.2024.09.002","DOIUrl":"10.1016/j.bulcan.2024.09.002","url":null,"abstract":"Triple negative breast cancer (TNBC) is defined by the absence of expression of estrogen and progesterone receptors, as well as the absence of overexpression of HER2. Accounting for 10 to 15% of breast cancers, it remains characterized by an aggressive phenotype with an increased risk of early recurrence and overall survival less favorable compared to other subtypes. The challenges in management and therapeutic evolution are likely related to the demonstrated high biological heterogeneity of this subtype. Regarding therapeutic management, chemotherapy remains the cornerstone of TNBC treatment. In the early stage, the neoadjuvant strategy is the standard, allowing adaptation of the adjuvant sequence depending on whether a complete histological response is achieved or not. Dose-dense chemotherapy regimens and the addition of carboplatin have been associated with an improvement in these response rates. Furthermore, immunotherapy, particularly pembrolizumab, has shown significant benefits in terms of recurrence-free survival. In the metastatic setting, the role of theranostic markers is now established, allowing access to immunotherapy (pembrolizumab if CPS PD-L1>10%) or PARP inhibitors (in case of constitutional BRCA mutation). Antibody-drug conjugates are gradually moving up the lines, offering promising prospects in these complex situations. In conclusion, despite recent progress, TNBC remains a major clinical challenge. A better understanding of its biology and a personalized therapeutic approach are essential to improve clinical outcomes for patients with this aggressive form of breast cancer.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"82-99"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Setting up haploidentical hematopoietic cell transplantation in low- and middle-income countries: The Recommendations of the Francophone Society of Bone Marrow and Cellular Therapy (SFGM-TC)]. [在中低收入国家开展单倍体造血细胞移植：法语国家骨髓和细胞治疗协会（SFGM-TC）的建议]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-10-18 DOI: 10.1016/j.bulcan.2024.09.001

Fati Hamzy, Patrice Chevallier, Bénédicte Bruno, Valérie Coiteux, Maria El Kababri, Ahmad Ibrahim, Anas Oudrhiri, Ibrahim Yakoub-Agha, Mohamed-Amine Bekadja

{"title":"[Setting up haploidentical hematopoietic cell transplantation in low- and middle-income countries: The Recommendations of the Francophone Society of Bone Marrow and Cellular Therapy (SFGM-TC)].","authors":"Fati Hamzy, Patrice Chevallier, Bénédicte Bruno, Valérie Coiteux, Maria El Kababri, Ahmad Ibrahim, Anas Oudrhiri, Ibrahim Yakoub-Agha, Mohamed-Amine Bekadja","doi":"10.1016/j.bulcan.2024.09.001","DOIUrl":"10.1016/j.bulcan.2024.09.001","url":null,"abstract":"Nowadays, haploidentical hematopoietic cell transplantation (haplo-HCT) has been routinely used worldwide. However, this procedure is still rarely proposed in low- or middle-income countries. During the 13th annual harmonization workshops of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), a designated working group has proposed recommendations on how to set up such a transplantation in these countries. This was based on a review of the literature and expert-opinion as well as the previously published workshop on haplo-HCT of SFGM-TC (2016). Haploidentical donors appear to be a first alternative to HLA-matched siblings since the access to unrelated donor international registries are limited for several countries. While the procedure has the advantage of immediate access to several potential donors and of low cost, Haplo-HCT should be performed only in centers with a good experience of HLA-matched related transplantation (>10/year). In the absence of an HLA-matched related donor, haplo-HCT should be offered to all patients who are candidate for allo-HCT. Transplantation modalities should follow the conventional procedures with post-transplant cyclophosphamide as GVHD prophylaxis. Conditioning can be myeloablative or not according to each case. Our recommendations are intended to be general in scope and applicable to the majority of allo-HCT centers in these countries. An evaluation at regular basis is needed to assess the feasibility and to improve results.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S146-S156"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Letter to young oncologists of the 21st century]. [致 21 世纪年轻肿瘤学家的一封信]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-12-18 DOI: 10.1016/j.bulcan.2024.12.006

Thierry Philip

引用次数: 0